Immune Therapeutics, Inc. (OTCMKTS:IMUN) Files An 8-K Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement

Settlement Agreement

On or around April 4, 2017, Immune Therapeutics, Inc. (the
Company) entered into a settlement agreement (the Settlement
Agreement) with Mr. Marshall Faulk (Faulk). to the Settlement
Agreement, Faulk agreed to assign a promissory note issued by the
Company to Faulk on December 10, 2015 in the principal amount of
$100,000.00 (the Prior Note), under which the Company was in
default, to Mr. Robert J. Dailey (Dailey) to a Debt Purchase and
Exchange Agreement (the Exchange Agreement) between the parties.
In addition, Faulk agreed to waive all claims against the Company
relating to the Prior Note. In consideration for the foregoing,
the Company agreed to issue Faulk 2,000,000 restricted common
shares.

Debt Purchase and Exchange Agreement

On or around April 5, 2017, the Company entered into the Exchange
Agreement with Faulk and Dailey. to the exchange Agreement,
Dailey agreed to purchase the Prior Note from Faulk for
$150,000.00 and Faulk agreed to assign to Dailey all of his
rights under the Prior Note. Further, the Company agreed to issue
Dailey a new promissory note in the principal amount of $150,000
(Exchange Note). Dailey shall accrue interest at a rate of 2% per
annum under the Exchange Note, which shall mature one year from
its issuance. Notwithstanding, the maturity of the Exchange Note
shall be accelerated upon the occurrence of any of the following:
(i) the Company shall raise investment funds in excess of
$1,500,000.00, (ii) the Company shall up-list to NASDAQ, or (iii)
the Company shall receive gross revenues in excess of
$1,500,000.00, at which point it will pay Dailey 5% of such gross
revenues on a monthly basis. Unlike the Prior Note, the Exchange
Note is not convertible into shares of the Company.

Item 2.03 Creation of a Direct Financial Obligation or an
Obligation under an Off-Balance Sheet Arrangement of a
Registrant

Please see Item 1.01 Debt Purchase and Exchange
Agreement, incorporated herein by reference, for discussion
relating to the Note, which was issued by the Company on or
around April 5, 2017.

Item 3.02 Unregistered Sales of Equity
Securities

Please see Item 1.01 Settlement Agreement, incorporated
herein by reference, for discussion relating to the issuance of
2,000,000 restricted shares to Marshall Faulk. These shares were
issued to the exemption from registration found in Section
4(a)(2) of the Securities Act of 1933.

Item 8.01. Other Events.

On April 12, 2017, the Company issued a press release in the form
attached hereto as Exhibit 99.1 regarding the foregoing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. The following exhibits are filed herewith.

About Immune Therapeutics, Inc. (OTCMKTS:IMUN)

Immune Therapeutics, Inc. is a biotechnology company. The Company is involved in the manufacturing, distribution and marketing of therapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system using its patented immunotherapy. The Company’s products and immunotherapy technologies are designed to improve the treatment of cancer, infections, such as human immunodeficiency virus (HIV)/acquired immuno deficiency syndrome (AIDS), chronic inflammatory diseases and autoimmune diseases. Its technology platform is built on various immunotherapies, such as Low Dose Naltrexone (LDN) and Methionine-Enkephalin (MENK). Its technology offers treatment for a range of cancers. The Company’s clinical programs involve immunotherapy with Methionine-Enkephalin (MENK) (sometimes referred to as opioid growth factor) and its Low Dose Naltrexone (LDN) product or LodonalTM, which stimulates the immune system even in patients with advanced cancer.

Immune Therapeutics, Inc. (OTCMKTS:IMUN) Recent Trading Information

Immune Therapeutics, Inc. (OTCMKTS:IMUN) closed its last trading session up +0.0070 at 0.0430 with 4,370,006 shares trading hands.